CA
NZ
UK
AU
IND
US
Neither Medicus Pharma (NASDAQ:MDCX) nor Azitra (NYSE American:AZTR) sells an approved drug. For clinical-stage companies like these, value depends mostly on milestones: a regulator clearing a study, a trial reporting data, a program being dropped or prioritized. Each one changes the odds of reaching …
Small biotechs often reach a point where the original plan stops working. A lead drug fails, aPartnershipfalls through or cash runs short, and management must choose whether to narrow the pipeline, sell assets, merge or become a different business. Matinas BioPharma (NYSE American:MTNB) and …
The "pharmaceutical" label covers a wide range of companies. Some sell a few branded prescription products; others make bulk ingredients in large volumes for low prices. Scienture Holdings (NASDAQ:SCNX) and BGM Group (NASDAQ:BGM) show how different those models can be: one is a U.S. …
CancerDrug Developmentcosts a lot, takes years and fails often, and small companies in the field can look alike from the outside. Silexion Therapeutics (NASDAQ:SLXN) and Context Therapeutics (NASDAQ:CNTX) are both Nasdaq-listed oncology developers, but they approach cancer in different ways. Silexion is developing an …
A drug developer's story is only as strong as the evidence behind it. Regulators, partners and eventually payers want controlled data showing that a product works and is safe. AIM ImmunoTech (NYSE American:AIM) and GeoVax Labs (NASDAQ:GOVX) show two different evidence paths: AIM is …
Accuray (NASDAQ:ARAY) and iTonic Holdings (NASDAQ:ITOC) both make technology for radiation-based cancer treatment, yet they are about as far apart in scale as two Nasdaq-listed healthcare companies can be. Accuray reported roughly $400 million of annual revenue and sells large treatment systems to hospitals …
Late-stageClinical Trialsare the moments that can redefine a small biotech, and both aTyr Pharma (NASDAQ:ATYR) and Soligenix (NASDAQ:SNGX) have lived through one in the past year. Each company saw a Phase 3 study fall short of its main goal, and each has since narrowed …
Instinct Bio Technical (NASDAQ:BIOT) and DocGo (NASDAQ:DCGO) both sit under the healthcare label, but little else connects them. One is a Tokyo-based regenerative medicine and stem cell skincare company that reached Nasdaq through a SPAC merger in July 2026. The other is a U.S. …
Some small healthcare companies are defined by one drug and one trial. Others are built more like holding structures, collecting licensed assets, minority stakes and partnerships. CDT Equity (NASDAQ:CDT) and Theriva Biologics (NYSE American:TOVX) fall on either side of that divide, and both operate …
Endovia Health Sciences (NYSE American:EDVA) and ALPS Group (NASDAQ:ALPS) are both new to the healthcare sector, but they got there in different ways. Endovia renamed itself in August 2026 after years as a beverage company and now aims to develop cannabinoid-based medicines. ALPS Group, …
Please wait processing your request...